CollPlant (NASDAQ: CLGN), a regenerative medicine company, announced on Friday its financial results for the third quarter ended 30 September 2019.
The company reported revenues for the three months ended 30 September 2019 at USD679,000, up 203% compared to the year-ago period.
The firm posted gross profit for the three months ended 30 September 2019 at USD53,000, down 64% compared to the same period in 2018.
Comprehensive loss for the third quarter of 2019 was USD3.2m, or USD0.69 per share, compared to a comprehensive loss of USD1.3m, or USD0.29 per share, for the third quarter of 2018.
Yehiel Tal, CollPlant's chief executive officer, said, 'Significant developments during the third quarter of 2019 included our progress in the development of a 3D bioprinted implant for the regeneration of breast tissue, and our USD5.5m financing round which included new investors who have deep expertise in 3D printing.'
Thermo Fisher Scientific to acquire Clario Holdings, expanding clinical data capabilities
Nanoform and Revio Therapeutics partner to develop long-acting hydrogel therapy for glioma
Cumberland Pharmaceuticals adds FDA-approved oral capsule for H. pylori to commercial portfolio
IP Group positions for future royalties following Pfizer's USD7.3bn acquisition of Metsera
AstraZeneca strikes landmark drug pricing deal with US Government
Fusion Antibodies secures multi-target humanisation contract with global pharmaceutical client
Genmab to acquire Merus in USD8bn deal to strengthen oncology pipeline
Wolters Kluwer launches UpToDate Expert AI to deliver trusted GenAI clinical decision support
CVS Health declares unchanged quarterly dividend
ALK partners with GenSci to expand allergy immunotherapy market in China
Curatis secures Swiss distribution deal with Phoenix Labs
Innocan Pharma reports 'positive swing' in operating profitability for first half of 2025
Wolters Kluwer boosts medical research efficiency with Ovid AI summarisation